Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker TAK · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis NCT07286058 · Psoriatic Arthritis Zasocitinib | TAK Takeda | Phase 3 | Recruiting | 1,182 | Dec 18, 2029 | Registry ↗ |
| Nov 12, 2026 | A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium NCT06677892 · Cytomegalovirus (CMV) No Intervention | TAK Takeda | — | Completed was active, not recruiting | 66 | Aug 1, 2026 | Registry ↗ |
| Nov 12, 2026 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines NCT06671483 · Psoriatic Arthritis Zasocitinib, Active Comparator | TAK Takeda | Phase 3 | Active, not recruiting was recruiting | 1,583 | May 18, 2027 | Registry ↗ |
| Nov 12, 2026 | Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Li… NCT06165341 · Alpha1-Antitrypsin Deficiency Fazirsiran Injection, Placebo | TAK Takeda | Phase 3 | Recruiting | 50 | Aug 26, 2028 | Registry ↗ |
| Nov 12, 2026 | An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help Peo… NCT05899673 · Alpha1-Antitrypsin Deficiency Fazirsiran Injection | TAK Takeda | Phase 3 | Active, not recruiting | 200 | May 2, 2033 | Registry ↗ |
| Nov 12, 2026 | A Survey of Lanadelumab in Participants With Hereditary Angioedema NCT05397431 · Hereditary Angioedema (HAE) Lanadelumab | TAK Takeda | — | Completed was active, not recruiting | 157 | Oct 27, 2026 | Registry ↗ |
| Nov 12, 2026 | A Survey of Darvadstrocel in People With Crohn's Disease NCT05113095 · Crohn's Disease Darvadstrocel | TAK Takeda | — | Recruiting | 275 | Dec 31, 2029 | Registry ↗ |
| Nov 10, 2026 | Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell A… NCT04530123 · Celiac Disease Placebo, TAK-101 | TAK Takeda | Phase 2 | Completed | 102 | Dec 9, 2025 | Registry ↗ |
| Nov 10, 2026 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants… NCT02979522 · Hodgkin Disease Brentuximab vedotin, Doxorubicin | TAK Takeda | Phase 1/2 | Active, not recruiting | 59 | May 5, 2020 | Registry ↗ |
| Nov 9, 2026 | A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of S… NCT07263685 · Hereditary Angioedema (HAE) No intervention | TAK Takeda | — | Completed was recruiting | 47 | Nov 3, 2026 | Registry ↗ |
| Nov 9, 2026 | A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea NCT06550882 · Acquired Hemophilia A OBIZUR | TAK Takeda | — | Recruiting | 11 | Dec 31, 2028 | Registry ↗ |
| Nov 6, 2026 | A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ru… NCT07623161 · Myelofibrosis, Anemia Placebo, Elritercept | TAK Takeda | Phase 3 | Recruiting | 324 | Dec 7, 2029 | Registry ↗ |
| Nov 6, 2026 | A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transpl… NCT07613359 · Antibody-Mediated Rejection (AMR) Mezagitamab, Placebo | TAK Takeda | Phase 2 | Recruiting was not yet recruiting | 36 | Jan 15, 2029 | Registry ↗ |
| Nov 6, 2026 | A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodys… NCT07422480 · Myelodysplastic Syndrome, Anemia Elritercept, Epoetin Alfa | TAK Takeda | Phase 3 | Recruiting | 300 | Apr 30, 2029 | Registry ↗ |
| Nov 6, 2026 | A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated… NCT07353099 · Thrombotic Thrombocytopenic Purpura (TTP) No Intervention | TAK Takeda | — | Recruiting | 50 | Apr 1, 2030 | Registry ↗ |
| Nov 6, 2026 | A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantat… NCT06555432 · Cytomegalovirus (CMV) LIVTENCITY | TAK Takeda | — | Recruiting | 168 | Oct 1, 2028 | Registry ↗ |
| Nov 6, 2026 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysp… NCT06499285 · Myelodysplastic Syndromes Elritercept, Placebo | TAK Takeda | Phase 3 | Recruiting | 225 | Sep 15, 2028 | Registry ↗ |
| Nov 5, 2026 | A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia NCT07646678 · Idiopathic Hypersomnia, Narcolepsy Type 1 TAK-360, Placebo | TAK Takeda | Phase 2/3 | Recruiting | 500 | Jun 15, 2031 | Registry ↗ |
| Nov 4, 2026 | A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis NCT07752108 · Palmoplantar Psoriasis Zasocitinib | TAK Takeda | Phase 3 | Not yet recruiting | 40 | May 30, 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of Zasocitinib in Adults With Hidradenitis Suppurativa NCT07244263 · Hidradenitis Suppurativa Zasocitinib (Dose A), Placebo | TAK Takeda | Phase 2 | Active, not recruiting was recruiting | 91 | Feb 5, 2027 | Registry ↗ |
| Nov 4, 2026 | A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy NCT06963827 · Kidney Disease Mezagitamab, Placebo | TAK Takeda | Phase 3 | Recruiting | 347 | Sep 7, 2028 | Registry ↗ |
| Nov 4, 2026 | A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia NCT06722235 · Immune Thrombocytopenic Purpura (ITP) Mezagitamab, Placebo | TAK Takeda | Phase 3 | Recruiting | 171 | Mar 16, 2028 | Registry ↗ |
| Nov 4, 2026 | A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psori… NCT06323356 · Generalized Pustular Psoriasis, Erythrodermic Psoriasis TAK-279 | TAK Takeda | Phase 3 | Completed | 18 | Oct 17, 2025 | Registry ↗ |
| Nov 3, 2026 | A Study of Zasocitinib in Adults With Nonsegmental Vitiligo NCT07108283 · Nonsegmental Vitiligo Zasocitinib, Placebo | TAK Takeda | Phase 2 | Active, not recruiting was recruiting | 207 | Mar 26, 2027 | Registry ↗ |
| Nov 3, 2026 | A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) NCT06798012 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (… TAK-411 | TAK Takeda | Phase 2 | Recruiting | 36 | Dec 2, 2027 | Registry ↗ |
| Nov 2, 2026 | A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer NCT07217301 · IO Resistant Squamous and Nonsquamous NSCLC TAK-928, Control Arm | TAK Takeda | Phase 3 | Recruiting | 1,200 | Nov 1, 2028 | Registry ↗ |
| Nov 2, 2026 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participant… NCT06233461 · Crohn's Disease TAK-279, Placebo | TAK Takeda | Phase 2 | Recruiting | 268 | Feb 17, 2027 | Registry ↗ |
| Nov 2, 2026 | A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease NCT05837897 · Crohn's Disease Vedolizumab IV, Placebo | TAK Takeda | Phase 3 | Recruiting | 408 | Mar 8, 2030 | Registry ↗ |
| Oct 30, 2026 | A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy NCT07363720 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy TAK-861, Placebo | TAK Takeda | Phase 3 | Active, not recruiting | 98 | Dec 17, 2026 | Registry ↗ |
| Oct 30, 2026 | Epidemiology of Narcolepsy Type 1 and Type 2 in Spain NCT07299097 · Narcolepsy Type 1, Narcolepsy Type 2 No intervention | TAK Takeda | — | Active, not recruiting | 402 | Dec 31, 2026 | Registry ↗ |
| Oct 30, 2026 | A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia NCT06948318 · Immune Thrombocytopenic Purpura (ITP) Mezagitamab | TAK Takeda | Phase 3 | Recruiting | 150 | Jul 29, 2029 | Registry ↗ |
| Oct 30, 2026 | A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer NCT03807778 · Non-Small Cell Lung Cancer Mobocertinib | TAK Takeda | Phase 1 | Active, not recruiting | 53 | Nov 8, 2021 | Registry ↗ |
| Oct 29, 2026 | A Study About Treatment Use in Adults With Narcolepsy Type 1 (NT1) in Europe and Canada NCT07903220 · Narcolepsy Type 1 No intervention | TAK Takeda | — | Not yet recruiting | 400 | Sep 30, 2027 | Registry ↗ |
| Oct 29, 2026 | A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder NCT07204314 · Major Depressive Disorder Vortioxetine tablets, Placebo tablets | TAK Takeda | Phase 3 | Recruiting | 180 | Sep 30, 2029 | Registry ↗ |
| Oct 28, 2026 | A Study of TAK-505 in Adults With Solid Tumors NCT07436728 · Malignant Solid Tumors TAK-505 | TAK Takeda | Phase 1/2 | Recruiting | 151 | Aug 18, 2030 | Registry ↗ |
| Oct 28, 2026 | A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes NCT07319845 · Myelodysplastic Syndromes TAK-226 | TAK Takeda | Phase 2 | Recruiting | 42 | Jun 26, 2028 | Registry ↗ |
| Oct 28, 2026 | A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Commun… NCT06581328 · Ulcerative Colitis, Crohn's Disease Vedolizumab IV, Vedolizumab SC | TAK Takeda | Phase 4 | Recruiting | 200 | May 1, 2027 | Registry ↗ |
| Oct 28, 2026 | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer NCT02716116 · Carcinoma, Non-Small-Cell Lung TAK-788 | TAK Takeda | Phase 1/2 | Completed | 324 | Sep 29, 2026 | Registry ↗ |
| Oct 27, 2026 | A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) NCT07871721 · Psoriatic Arthritis Placebo, Zasocitinib | TAK Takeda | Phase 3 | Not yet recruiting | 644 | Apr 18, 2030 | Registry ↗ |
| Oct 26, 2026 | A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) NCT06095128 · Ulcerative Colitis Vedolizumab, Tofacitinib | TAK Takeda | Phase 4 | Active, not recruiting | 60 | Jul 9, 2027 | Registry ↗ |
| Oct 23, 2026 | A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults Wit… NCT06045754 · Crohn's Disease Vedolizumab, Adalimumab | TAK Takeda | Phase 4 | Active, not recruiting | 50 | Jun 28, 2027 | Registry ↗ |
| Oct 23, 2026 | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (… NCT04129502 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) TAK-788, Pemetrexed | TAK Takeda | Phase 3 | Completed | 354 | Sep 22, 2026 | Registry ↗ |
| Oct 22, 2026 | A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults Wi… NCT04420884 · Solid Neoplasms Dazostinag, Pembrolizumab | TAK Takeda | Phase 1/2 | Completed | 248 | Mar 30, 2026 | Registry ↗ |
| Oct 20, 2026 | A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Pur… NCT07429942 · Thrombotic Thrombocytopenic Purpura (TTP) No Intervention | TAK Takeda | — | Recruiting | 94 | Oct 30, 2026 | Registry ↗ |
| Oct 19, 2026 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysp… NCT04419649 · Myelodysplastic Syndromes, Cytopenia Elritercept | TAK Takeda | Phase 2 | Recruiting | 210 | Oct 30, 2029 | Registry ↗ |
| Oct 15, 2026 | A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea NCT07445087 · Hereditary Angioedema (HAE) No intervention | TAK Takeda | — | Recruiting | 35 | Feb 29, 2032 | Registry ↗ |
| Oct 15, 2026 | A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease NCT07250815 · Ulcerative Colitis, Crohn's Disease No intervention | TAK Takeda | — | Withdrawn | 0 | Dec 15, 2026 | Registry ↗ |
| Oct 14, 2026 | A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors NCT07205718 · Advanced or Metastatic Solid Tumors TAK-188 | TAK Takeda | Phase 1/2 | Recruiting | 273 | Dec 26, 2028 | Registry ↗ |
| Oct 14, 2026 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Bi… NCT06671496 · Psoriatic Arthritis Zasocitinib, Placebo | TAK Takeda | Phase 3 | Active, not recruiting | 601 | May 18, 2027 | Registry ↗ |
| Oct 13, 2026 | A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Mu… NCT06980480 · Multiple Myeloma, Secondary Immunodeficiency IGI, 10% | TAK Takeda | Phase 3 | Recruiting | 183 | Sep 11, 2028 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:06 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances